The protective effects of CD39 overexpression in multiple low-dose streptozotocin-induced diabetes in mice
Diabetes, ISSN: 0012-1797, Vol: 62, Issue: 6, Page: 2026-2035
2013
- 37Citations
- 29Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations37
- Citation Indexes37
- 37
- CrossRef26
- Captures29
- Readers29
- 29
Article Description
Islet allograft survival limits the long-term success of islet transplantation as a potential curative therapy for type 1 diabetes. A number of factors compromise islet survival, including recurrent diabetes. We investigated whether CD39, an ectonucleotidase that promotes the generation of extracellular adenosine, would mitigate diabetes in the T cell-mediated multiple low-dose streptozotocin (MLDS) model. Mice null for CD39 (CD39KO), wild-type mice (WT), and mice overexpressing CD39 (CD39TG) were subjected to MLDS. Adoptive transfer experiments were performed to delineate the efficacy of tissue-restricted overexpression of CD39. The role of adenosine signaling was examined using mutant mice and pharmacological inhibition. The susceptibility to MLDS-induced diabetes was influenced by the level of expression of CD39. CD39KO mice developed diabetes more rapidly and with higher frequency than WT mice. In contrast, CD39TG mice were protected. CD39 overexpression conferred protection through the activation of adenosine 2A receptor and adenosine 2B receptor. Adoptive transfer experiments indicated that tissue-restricted overexpression of CD39 conferred robust protection, suggesting that this may be a useful strategy to protect islet grafts from T cell-mediated injury. © 2013 by the American Diabetes Association.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84878218001&origin=inward; http://dx.doi.org/10.2337/db12-0625; http://www.ncbi.nlm.nih.gov/pubmed/23364452; https://diabetesjournals.org/diabetes/article/62/6/2026/15642/The-Protective-Effects-of-CD39-Overexpression-in; https://dx.doi.org/10.2337/db12-0625; http://diabetes.diabetesjournals.org/cgi/doi/10.2337/db12-0625; http://diabetes.diabetesjournals.org/content/62/6/2026; http://diabetes.diabetesjournals.org/content/62/6/2026.abstract; http://diabetes.diabetesjournals.org/content/62/6/2026.full.pdf; https://diabetes.diabetesjournals.org/content/62/6/2026; https://diabetes.diabetesjournals.org/content/62/6/2026.abstract; https://diabetes.diabetesjournals.org/content/diabetes/62/6/2026.full.pdf; http://diabetes.diabetesjournals.org/lookup/doi/10.2337/db12-0625
American Diabetes Association
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know